Highlights from this issue

Abstract

INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY Castellanos et al evaluated outcome in six eyes of premature infants treated with intravitreal ranibizumab injections for retinopathy of prematurity (ROP) with highrisk prethreshold or threshold ROP with plus disease. All eyes showed complete resolution of neovasclurisation after a single injection. The anti-angiogenic intravitreal injections allowed for continued normal vessel growth into the peripheral retina, without any signs of disease recurrence or progression, and systemic adverse effects over 3 years of follow up.